BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 9050976)

  • 1. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension.
    Küppers HE; Jäger BA; Luszick JH; Gräve MA; Hughes PR; Kaan EC
    J Hypertens; 1997 Jan; 15(1):93-7. PubMed ID: 9050976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild to moderate essential hypertension.
    Prichard BN; Jäger BA; Luszick JH; Küster LJ; Verboom CN; Hughes PR; Sauermann W; Küppers HE
    Blood Press; 2002; 11(3):166-72. PubMed ID: 12126263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience.
    Ollivier JP; Christen MO
    J Cardiovasc Pharmacol; 1994; 24 Suppl 1():S39-48. PubMed ID: 7533226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension.
    Himmelmann A; Keinänen-Kiukaanniemi S; Wester A; Redón J; Asmar R; Hedner T;
    Blood Press; 2001; 10(1):43-51. PubMed ID: 11332334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
    Tikkanen I; Omvik P; Jensen HA
    J Hypertens; 1995 Nov; 13(11):1343-51. PubMed ID: 8984133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-dose reserpine/thiazide combination in first-line treatment of hypertension: efficacy and safety compared to an ACE inhibitor.
    Griebenow R; Pittrow DB; Weidinger G; Mueller E; Mutschler E; Welzel D
    Blood Press; 1997 Sep; 6(5):299-306. PubMed ID: 9360001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An inpatient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension.
    Byyny RL; Merrill DD; Bradstreet TE; Sweet CS
    Cardiovasc Drugs Ther; 1996 Jul; 10(3):313-9. PubMed ID: 8877074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the efficacy and tolerability of telmisartan 40 mg vs. enalapril 10 mg in the treatment of mild-to-moderate hypertension: a multicentre, double-blind study in Taiwanese patients.
    Chen JH; Cheng JJ; Chen CY; Chiou HC; Huang TY; Tsai CD; Fu MM; Cherng WJ
    Int J Clin Pract Suppl; 2004 Dec; (145):29-34. PubMed ID: 15617456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Manidipine versus enalapril monotherapy in patients with hypertension and type 2 diabetes mellitus: a multicenter, randomized, double-blind, 24-week study.
    Luque Otero M; Martell Claros N;
    Clin Ther; 2005 Feb; 27(2):166-73. PubMed ID: 15811479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. The Eprosartan Multinational Study Group.
    Hedner T; Himmelmann A
    J Hypertens; 1999 Jan; 17(1):129-36. PubMed ID: 10100104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of eprosartan in severe hypertension. Eprosartan Multinational Study Group.
    Sega R
    Blood Press; 1999; 8(2):114-21. PubMed ID: 10451039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. I1 imidazoline agonists. General clinical pharmacology of imidazoline receptors: implications for the treatment of the elderly.
    Prichard BN; Graham BR
    Drugs Aging; 2000 Aug; 17(2):133-59. PubMed ID: 10984201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose response and safety of telmisartan in patients with mild to moderate hypertension.
    Smith DH; Matzek KM; Kempthorne-Rawson J
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 1):1380-90. PubMed ID: 11185637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.
    Karlberg BE; Lins LE; Hermansson K
    J Hypertens; 1999 Feb; 17(2):293-302. PubMed ID: 10067800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial.
    Derosa G; Cicero AF; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Fassi R; Fogari R
    Clin Ther; 2007 Apr; 29(4):602-10. PubMed ID: 17617283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Moxonidine vs. captopril in minor to intermediate hypertension. Double-blind study of effectiveness and tolerance].
    Lotti G; Gianrossi R
    Fortschr Med; 1993 Sep; 111(27):429-32. PubMed ID: 8225149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of blood pressure response to the combination of enalapril (single dose) and diltiazem ER (four different doses) in systemic hypertension.
    Applegate WB; Cohen JD; Wolfson P; Davis A; Green S
    Am J Cardiol; 1996 Jul; 78(1):51-5. PubMed ID: 8712118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.
    Wells T; Frame V; Soffer B; Shaw W; Zhang Z; Herrera P; Shahinfar S;
    J Clin Pharmacol; 2002 Aug; 42(8):870-80. PubMed ID: 12162469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-hour ambulatory blood pressure monitoring and spirapril in mild to severe essential hypertension: a randomized dose comparison.
    Vreugdenhil G; van Montfrans GA; Jacobs MC; de Bruijn JH; Veerman DP; van Es PN; Mellein B; Guitard C; Thien T; de Leeuw PW
    Blood Press Suppl; 1994; 2():23-30. PubMed ID: 8061842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
    Mallion JM; Omboni S; Barton J; Van Mieghem W; Narkiewicz K; Panzer PK; Puig JG; Stefanadis C; Zweiker R;
    Blood Press Suppl; 2011 Apr; 1():3-11. PubMed ID: 21091270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.